{"analyses":[{"ciLowerLimit":"63.8","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"148.8","estimateComment":"Ratio of geometric mean is calculated as Azacitidine 50 mg/m\\^2 / Azacitidine 25 mg/m\\^2 and expressed as a percentage.","groupDescription":"Geometric means, ratio and 90% CI of ratio of geometric means are from one way analysis of variance models on the nature log-transformed dose-normalized AUC0-inf, obtained on Day 1. Azacitidine 25 mg/m\\^2 is the reference group for comparisons.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of Geometric Means","paramValue":"97.4"},{"ciLowerLimit":"45.7","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"102.7","estimateComment":"Ratio of geometric mean is calculated as Azacitidine 75 mg/m\\^2 / Azacitidine 25 mg/m\\^2 and expressed as a percentage.","groupDescription":"Geometric means, ratio and 90% CI of ratio of geometric means are from one way analysis of variance models on the nature log-transformed dose-normalized AUC0-inf, obtained on Day 1. Azacitidine 25 mg/m\\^2 is the reference group for comparisons.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of Geometric Means","paramValue":"68.5"},{"ciLowerLimit":"54.5","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"127.1","estimateComment":"Ratio of geometric mean is calculated as Azacitidine 100 mg/m\\^2 / Azacitidine 25 mg/m\\^2 and expressed as a percentage.","groupDescription":"Geometric means, ratio and 90% CI of ratio of geometric means are from one way analysis of variance models on the nature log-transformed dose-normalized AUC0-inf, obtained on Day 1. Azacitidine 25 mg/m\\^2 is the reference group for comparisons.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of Geometric Means","paramValue":"83.2"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.79","value":"460.47"},{"groupId":"OG001","spread":"30.93","value":"897.42"},{"groupId":"OG002","spread":"39.05","value":"945.50"},{"groupId":"OG003","spread":"23.96","value":"1533.37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"The area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) for azacitidine after a single dose, calculated by the linear trapezoidal rule and extrapolated to infinity according to the following equation:\n\nAUC0-inf = AUC0-t + (Ct/ke), where Ct is the last quantifiable concentration and ke = elimination rate constant.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with normal renal function (defined as creatinine clearance \\> 80 mL/min/1.73m\\^2) received a single subcutaneous dose of azacitidine 25 mg/m\\^2 on Day 1.","id":"OG000","title":"Azacitidine 25 mg/m^2"},{"description":"Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m\\^2 on Day 1.","id":"OG001","title":"Azacitidine 50 mg/m^2"},{"description":"Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m\\^2 on Days 1 to 5.","id":"OG002","title":"Azacitidine 75 mg/m^2"},{"description":"Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m\\^2 on Day 1.","id":"OG003","title":"Azacitidine 100 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Population, consisting of all participants with evaluable plasma or urine concentration data for azacitidine. This analysis was performed for participants with normal renal function only.","reportingStatus":"POSTED","timeFrame":"Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose","title":"Area Under the Plasma Concentration-time Curve From Time Zero to Infinity","type":"PRIMARY","unitOfMeasure":"ng*hr/mL"}